Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of the study is to evaluate the effectiveness of a post-diagnostic psychoeducational intervention in increasing the sense of self-efficacy of adults diagnosed with Autism Spectrum Disorder-Without associated Intellectual Disability
Full description
Secondary objectives
The other objectives of this study are :
Conduct of research The study will be offered to individuals diagnosed with autism spectrum disorder without associated intellectual developmental disabilities in adulthood.
After signing the consent form and verifying the eligibility criteria, participants will be randomized into the waiting list group or the intervention group.
In the intervention group : the participant will receive 10 one-hour individual sessions, bi-monthly, with an assessment at midterm (T1 : T0+~2.5 months), at the end of the intervention (T2 : T0 +~5 months) and 3 months after the intervention (T3 : T0 +~8 months).
In the waiting list group : the participant will receive the intervention at the exit of the research protocol (after T3).
At conclusion and at each visit, participants will complete questionnaires and scales defined in the protocol.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participant aged 18 years and older at the time of inclusion in the study
Participant with a diagnosis of Autism Spectrum Disorder - Without associated Intellectual Disability (intelligence quotient > 80) made by a specialized 2nd (1) or 3rd (2) line team according to the recommendations of the Haute Autorité de la Santé (HAS)
Diagnosis of Autism Spectrum Disorder - Without associated Intellectual Disability obtained in adulthood (≥ 18 years) within 15 months prior to inclusion
Participant able to understand the objectives and risks of the research and having signed a consent to participate in the study
Participant affiliated with a social security plan or beneficiary of such a plan
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
66 participants in 2 patient groups
Loading...
Central trial contact
ERIC BIZET, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal